AstraZeneca's lung cancer drug approved in China: AstraZeneca said that its Tagrisso medicine has been approved in China for the treatment of early lung cancer. The UK-based pharmaceutical giant said Tagrisso is the first such drug to have received approval in China, as well as the only one to have shown efficacy against the disease in a global trial.
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
AstraZeneca’s Tagrisso was approved in China for lung cancer treatment
The FTSE 100 company added that the approval is based on the positive results coming from the Adaura Phase 3 trial, where Tagrisso was proven to reduce the risk of disease recurrence or death by 80%.
